1. A compound having formula (I):
or a pharmaceutically acceptable salt thereof wherein:
the dashed bond indicates a single or double bond;
R1is a member selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, and halogen;
R2 is a member selected from the group consisting of hydrogen, C1-8 alkyl, C3cycloalkyl, C1-8 haloalkyl, halogen, CN, and C1-8 alkoxy;
R3 is a member selected from the group consisting of H, C1-4 lower alkyl and C1-4 haloalkyl;
R4 is a member selected from the group consisting of H, C1-8 alkyl, C1-8 hydroxyalkyl, and C1-8 hydroxyalkyl;
the subscripts n are each independently selected from the group consisting of 0, 1, 2 and 3;
the subscript m is 1;
each A is independently C or N, and at least one A is N;
B is C(O),
Q, W, and Z are independently C, CH, or N with the exception that Q and W may not both be N in the same compound;
X is C, CH or N;
Y is N;
R5 and R6 are each independently absent or are a member selected from the group consisting of H, OH, NH2,halogen, C1-8 alkyl, C1-8 hydroxyalkyl, and C1-8 alkyl- NH2;
R7 is absent or a member selected from the group consisting of H, halogen, C1-8 alkyl and C1-8 haloalkyl;
R8 is absent or a member selected from the group consisting of H, OH, NH2, NHRa, CN, C1-4 aminoalkyl, C1-4 hydroxyalkyl and C1-4 alkyl;
R9 is absent or a member selected from the group consisting of H, CF3,C1-4 alkyl, CN, and \u2014CO2Ra;
R10 is absent or a member selected from the group consisting of H, CF3, C1- 4 alkyl and CN; and wherein
Ra is selected from the group consisting of H, and C1-8 alkyl.
2. A compound of claim 1, wherein X is selected from the group consisting of C and CH.
3. A compound of claim 2, wherein X is C.
4. A compound of claim 2, wherein X is C, and the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl.
5. A compound of claim 2, wherein X is C, and the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; and at least one of R5, R6 and R7 is other than hydrogen.
6. A compound of claim 1, wherein each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl, and R3 is methyl.
7. A compound of claim 1, wherein Y is N, and X is N.
8. A compound of claim 7, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl.
9. A compound of claim 7, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl, and at least one of R5, R6 and R7 is other than hydrogen.
10. A compound of claim 7, wherein each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl, and R3 is methyl.
11. A compound of claim 1, having formula (Ib):
12. A compound of claim 11, wherein X is C.
13. A compound of claim 11, wherein X is N, and Y is N.
14. A compound of claim 11, wherein each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl, and R3 is methyl.
15. A compound of claim 11, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
16. A compound of claim 11, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; at least one of R5, R6 and R7 is other than hydrogen; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
17. A compound of claim 1, having formula (Ic):
18. A compound of claim 17, wherein X is C.
19. A compound of claim 17, wherein X is N, and Y is N.
20. A compound of claim 17, wherein R1 is H and R9 is selected from the group consisting of H, CN and \u2014CO2Ra.
21. A compound of claim 17, wherein each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
22. A compound of claim 17, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
23. A compound of claim 17, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; at least one of R5, R6 and R7 is other than hydrogen; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
24. A compound of claim 1, having formula (Id):
25. A compound of claim 24, wherein X is C.
26. A compound of claim 24, wherein X is N, and Y is N.
27. A compound of claim 24, wherein R1 is H; one R4 is H and the other R4 is selected from the group consisting of H, C1-4 alkyl, and C1-4 hydroxyalkyl.
28. A compound of claim 24 wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
29. A compound of claim 24 wherein each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
30. A compound of claim 24 wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; at least one of R5, R6 and R7 is other than hydrogen; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl; and R3 is methyl.
31. A compound of claim 1, having formula (Ie):
32. A compound of claim 31, wherein X is C.
33. A compound of claim 31, wherein X is N, and Y is N.
34. A compound of claim 31, wherein R1 is selected from the group consisting of hydrogen and halogen; and R10 is hydrogen.
35. A compound of claim 31, wherein each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl.
36. A compound of claim 31, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl.
37. A compound of claim 31, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl and cyclohexyl; at least one of R5, R6 and R7 is other than hydrogen; each R2 is selected from the group consisting of fluoro, chloro, methyl and trifluoromethyl.
38. A compound of claim 1, selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
39. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1.
40. A pharmaceutical composition in accordance with claim 39, comprising a pharmaceutically acceptable excipient and a compound selected from the group consisting of:
41. A pharmaceutical composition in accordance with claim 39, comprising a pharmaceutically acceptable excipient and a compound selected from the group consisting of:
42. A pharmaceutical composition in accordance with claim 39, comprising a pharmaceutically acceptable excipient and a compound selected from the group consisting of:
43. A method of treating a disease or condition mediated by CCR(4) signalling, said method comprising administering to a subject in need thereof an efficacious amount of a compound of claim 1 wherein said disease or condition is selected from the group consisting of allergic diseases, psoriasis, atopic dermatitis and asthma.
44. A method in accordance with claim 43, wherein said compound is selected from the group consisting of:
45. A method in accordance with claim 43, wherein said compound is selected from the group consisting of:
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A color cathode-ray tube, comprising:
a phosphor screen forming on an inner surface of a panel and repeatedly forming a plurality of distinct color phosphor stripes;
an electron gun emitting a first, second, and third electron beams towards the phosphor screen; and
a shadow mask arranged in front of the phosphor screen facing the electron gun and forming a plurality of beam passage apertures for separating the electron beams, the shadow mask being mounted on an inside of the panel to satisfy a value Q of the following formula,
QnQ(n>4), (3SQ)(MpL),
with Q denoting a gap between the shadow mask and the phosphor screen, n denotes a natural number larger than or equal to four but not a multiple of 3, Q denoting a gap between a shadow mask and a phosphor screen, when the electron beams joined on a single beam passage aperture land in one group of the first, the second and third phosphor stripes being arranged on the phosphor screen side by side, S denoting a gap between a central electron beam and side electron beam in a main focus lens of the electron gun, Mp denoting a horizontal pitch of the shadow mask and L denoting a distance from the electron gun to the phosphor screen.
2. The cathode-ray tube of claim 1 with the first and third electron beams being side electron beams and the second electron beam being in the center, the first and third electron beams being joined at a single beam passage aperture after being emitted, arriving at corresponding first and third phosphor stripes beyond n1 stripes centering on the second phosphor stripe where the central second electron beam arrived.
3. The cathode-ray tube of claim 1, with the first, second, and third electron beams corresponding to red, green, and blue electron beams, respectively, and the first, second, and third phosphor stripes corresponding to red, green, and blue phosphor stripes, respectively.